WELLlife COVID-19/Influenza A&B Point of Care Rapid Test

WELLlife™ COVID-19 / Influenza A&B Tests* utilize advanced immunoassay technology to quickly and accurately differentiate between SARS-CoV-2, influenza A, and influenza B with a single nasal swab. Recommended for rapid diagnostics, these tests are essential tools for timely management of viral infections, supporting swift treatment decisions during the flu season and amidst public health concerns.

• Cost-effective: Differentiate between SARS-COV-2, influenza A, and influenza B antigens with a single test using an anterior nasal swab specimen.
• Rapid Results: available in 10 minutes allows for testing and treatment decision-making during the same office visit.
• Quality Assurance: The outstanding clinical performance, including built-in kit controls for external quality testing, enables physicians to make quicker and more confident decisions.
• Extended Detection Window: Offers a broader detection window for differentiation of SARS-COV-2, influenza A, and influenza B antigens within five days of symptom onset.
• Wide Storage Temperature: 36°F-86°F (2°C-30°C) allows for easier product storage.

*For use under Emergency Use Authorization (EUA) only

ViraDx™ SARS-CoV-2/Flu A+B Rapid Antigen Test is a lateral flow immunoassay intended for the in vitro rapid, simultaneous qualitative detection and differentiation of nucleocapsid protein antigen from SARS-CoV-2, influenza A and influenza B directly from anterior nasal or nasopharyngeal swab specimens collected from individuals, who are suspected of respiratory viral infection consistent with COVID-19 by their healthcare provider, within the first five (5) days of onset of symptoms.

HIGHLY CORRELATED TO PCR:

• COVID-19: Sensitivity (Anterior nasal swab) 93.8%; Specificity 100%
• COVID-19: Sensitivity (Nasopharyngeal) 93.1%; Specificity 100%
• Flu A: Sensitivity 92.2%; Specificity 94.2%
• Flu B: Sensitivity 90.0%; Specificity 94.3%